Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999842 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 424
- Enrollment target
NCT01999842: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT01999842 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 424 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (607% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01999842, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 424 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
Primary Outcome
The following aggregate variables will be calculated for each adjuvanted H7N9 vaccine group: • Seroconversion rates (SCR); • Seroprotection rates (SPR); • Mean Geometric Increase (MGI)
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Investigational H7N9 vaccine GSK3206641A
- BIOLOGICAL Investigational H7N9 vaccine GSK3206640A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2013-11-25 |
| Est. Completion | 2015-01-19 |
| Phase | Phase 1 |
What the finished NCT01999842 record still lists
NCT01999842 is an interventional study that assigns participants to a tested intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (607% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01999842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01999842 about?
NCT01999842 is a clinical study titled "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age". The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
What is the current status of trial NCT01999842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 424 participants. The study started on 2013-11-25. Estimated completion is 2015-01-19.
What interventions are being tested in trial NCT01999842?
The interventions under investigation include: Placebo (BIOLOGICAL), Investigational H7N9 vaccine GSK3206641A (BIOLOGICAL), Investigational H7N9 vaccine GSK3206640A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01999842?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01999842's enrollment target sits among peer trials
424 65th of 2000 higher than 1,936 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI